The study, conducted by Andrea Ortiz-Domínguez of the Department of Immunology at Jiménez Díaz Foundation University Hospital in Madrid and José R. Ortiz-Gómez of the Department of Anesthesiology at the University Hospital of Navarre in Pamplona, Spain, drew on an extraordinary volume of clinical data. Between 2018 and 2024, the researchers screened 46,804 consecutive surgical procedures at their tertiary referral hospital. After applying eligibility criteria for adults undergoing elective orthopedic surgery, 41,010 patients formed the complete analytical cohort—an unusually large sample for this field, where prediction models are often built on a few hundred patients at best. Of these patients, 377 experienced postoperative Richmond Agitation-Sedation Scale alterations, a relatively rare event that creates a formidable statistical challenge known as class imbalance, in which the overwhelming majority of negative cases can mask the signal the model is trying to detect.

The core methodological innovation of the work lies in its insistence on temporal validation, a rigorous form of testing that goes well beyond the internal cross-validation routinely reported in the prediction-model literature. The researchers divided their cohort chronologically rather than randomly: 34,271 patients treated earlier in the study period formed the derivation cohort in which the model was developed, while the 6,739 most recently treated patients were held out entirely as an independent temporal validation cohort. This design directly addresses one of the most common failure modes of clinical prediction models—overfitting to the idiosyncrasies of a particular dataset—which is why many published models collapse when confronted with new patients. By demonstrating stable performance in a cohort that did not exist statistically when the model was being fitted, the investigators provided evidence that their tool captures genuine biology rather than statistical noise.

The model itself is built from ten predictors that are available in virtually any preoperative clinic or laboratory panel anywhere in the world. Age and sex form the demographic backbone. Preoperative hemoglobin captures both oxygen-carrying capacity and broader physiological reserve. The remainder of the panel consists of white-cell-derived inflammatory indices that have attracted growing attention across perioperative and critical-care research: the neutrophil-to-lymphocyte ratio, the platelet-to-lymphocyte ratio, the lymphocyte-to-monocyte ratio, the systemic immune-inflammation index, the systemic inflammation response index, and a two-component representation of the basophil-to-lymphocyte ratio. Each of these indices is calculated simply by dividing one cell count by another from a standard complete blood count, which means the entire model can be computed in seconds from data that are already collected for every surgical patient.

The biological rationale for including these hematologic ratios is grounded in a substantial body of research linking systemic inflammation to postoperative delirium and related neurocognitive disturbances. Postoperative neuroinflammation is thought to arise when the surgical stress response and anesthetic exposure trigger peripheral immune activation, releasing cytokines and activating endothelial and microglial cells in the brain. In older adults, microglia—the brain’s resident immune cells—are already “primed” by aging and chronic low-grade inflammation, making them hyper-responsive to peripheral signals. An elevated neutrophil-to-lymphocyte ratio or systemic immune-inflammation index before surgery may therefore serve as a peripheral fingerprint of a nervous system that is primed to tip into agitation or pathological sedation under the additional inflammatory load of an operation. Prior studies have associated many of these individual ratios with postoperative delirium in cardiac, hip fracture, spinal, and vascular surgery populations, but the new study is distinctive in combining them within a single multivariable framework and testing the combined model at unprecedented scale.

The performance metrics reported for the temporal validation cohort are striking for a model of this simplicity. Discrimination—the model’s ability to separate patients who will develop RASS alterations from those who will not—was quantified by an area under the receiver operating characteristic curve of 0.892, a level usually associated with tools that meaningfully change clinical behavior. Calibration, which assesses whether predicted probabilities match observed event rates, was also satisfactory, with an intercept of 0.132 and a slope of 0.861, indicating that the model neither systematically over- nor under-predicted risk and preserved the ranking of individual risk across the probability spectrum. The Brier score, an overall measure combining discrimination and calibration that reflects average prediction error, was just 0.013—remarkably low, in part because the outcome is rare. The investigators supplemented these headline metrics with precision-recall analysis, which is the more honest way to evaluate performance under severe class imbalance, and with decision curve analysis, which estimates the net clinical benefit of acting on the model’s predictions across a range of threshold probabilities. Internal validation, performed with tenfold cross-validation and 2,000 bootstrap resamples, showed minimal optimism, meaning the model did not merely memorize its derivation data.

What makes the work particularly relevant to perioperative medicine is the deliberate constraint the authors placed on themselves: no intraoperative variables, no specialized biomarkers, no cognitive testing batteries, and no psychometric instruments. Existing delirium prediction tools frequently incorporate variables measured during or after surgery, such as anesthetic technique, intraoperative blood pressure trajectories, or postoperative inflammatory responses—information that arrives too late to inform preoperative planning. Others rely on biomarkers such as circulating tsRNAs, serum proteins, or genetic markers that are not available in routine practice. Still others use neuropsychological screening tests that require trained personnel and add time to an already stretched preoperative workup. A model that achieves strong discrimination using only data already sitting in the patient’s chart can be computed at the pre-anesthesia clinic visit, weeks before surgery, when there is still a genuine window for intervention.

That window matters because postoperative neurobehavioral disturbances are not merely inconvenient episodes to be managed at the bedside. Postoperative delirium and related neurocognitive disorders are associated with prolonged hospital stays, increased rates of discharge to institutional care, higher mortality, accelerated long-term cognitive decline, and substantial costs to health systems. The incidence of delirium after orthopedic procedures varies widely but can reach 10 to 40 percent in elderly patients, particularly after hip fracture surgery. Clinical practice guidelines emphasize that the most effective strategy against delirium is prevention through multicomponent interventions—optimizing hydration, nutrition, sensory aids, sleep hygiene, medication review, and early mobilization—applied to patients identified as high risk. A reliable preoperative risk score allows these resource-intensive interventions to be targeted at the patients who need them most, and potentially to prompt modifications such as optimization of anemia, adjustment of psychotropic medications, or intensified geriatric co-management.

The authors are appropriately measured about the limits of their work. Because the study is retrospective and single-center, the outcome definition depends on how RASS was measured in routine clinical documentation, and patient populations, anesthetic protocols, and documentation practices differ across institutions. The temporal validation, while rigorous, is not a substitute for external validation in independent hospitals, and the authors state explicitly that external validation is required before routine implementation. The extremely low event rate—fewer than 1 percent of patients—also means that even a model with an AUROC near 0.9 will generate false positives when applied broadly, which is why decision curve analysis and careful threshold selection will be central to any deployment. The dataset analyzed is not publicly available because it contains protected institutional clinical information, though de-identified data and the locked analytical workflow are available from the corresponding author upon reasonable request and ethics approval, a transparency measure the researchers say was designed to ensure computational reproducibility of every table and figure.

Beyond its immediate clinical utility, the study contributes to a shifting conceptual view of postoperative neurobehavioral instability: rather than an unpredictable complication of anesthesia, it is increasingly understood as a probabilistic event whose likelihood is inscribed in a patient’s systemic inflammatory and hematologic profile before surgery begins. If the model’s performance holds up in external, prospective cohorts, the humble complete blood count—already among the most common laboratory tests in the world—may become a routine gatekeeper for perioperative neurological risk stratification, quietly flagging the patients whose brains are most vulnerable to the turbulence of surgery. For now, the work stands as a methodological benchmark: a demonstration that with rigorous temporal validation, careful handling of class imbalance, and disciplined use of routine data, prediction models in perioperative medicine can be both clinically accessible and statistically trustworthy.

The team analyzed outcomes in older adults undergoing hip-fracture management, evaluating whether measurements taken around the time of surgery could forecast serious postoperative medical complications. They also tested the ratio’s ability to predict mortality at one year, aiming to translate laboratory data into clinically actionable risk stratification.

Technically, the study leverages the rationale that elevated D-dimer may correspond to thrombo-inflammatory processes triggered by trauma and operative stress, whereas reduced albumin may indicate impaired physiologic reserve. By computing their ratio, investigators hypothesized a stronger signal than either component alone, capturing both coagulation-driven risk and diminished recovery capacity.

The analysis framework compared patients across differing ratio levels and assessed how closely these groupings tracked adverse events. Statistical modeling was used to quantify associations between the perioperative ratio and subsequent serious complications, and to evaluate survival differences over a one-year follow-up.

Results indicate that the perioperative D-dimer-to-albumin ratio holds predictive value for postoperative serious medical complications in elderly hip-fracture patients. It also appears linked with longer-term survival, suggesting the ratio may function as an early warning tool when clinical deterioration is still preventable.

From a practical standpoint, the test is attractive because D-dimer and albumin are routinely measured in hospital laboratories. The ratio can therefore be calculated without additional assays, potentially supporting earlier identification of patients who may benefit from intensified monitoring or targeted interventions.

While retrospective designs cannot prove causality and may be influenced by unmeasured confounders, the findings align with the broader trend toward biomarker-based prognostication. If validated prospectively, the D-dimer-to-albumin ratio could become a viral “lab-to-bedside” metric for post-surgical risk alerts in geriatric orthopedics.

Subject of Research: Elderly patients with hip fracture undergoing surgery (perioperative risk prediction)

Article Title: Predictive value of perioperative D-dimer to albumin ratio for postoperative serious medical complications and one-year mortality in elderly patients with hip fracture: a retrospective study.

Article References: Liu, Y., Wang, C., Xiang, R. et al. Predictive value of perioperative D-dimer to albumin ratio for postoperative serious medical complications and one-year mortality in elderly patients with hip fracture: a retrospective study. BMC Geriatr (2026). https://doi.org/10.1186/s12877-026-07989-4

Image Credits: AI Generated

DOI: 10.1186/s12877-026-07989-4

Clinical trials investigating systemic therapies for uHCC have traditionally excluded patients with CP B cirrhosis, reflecting concerns regarding safety and diminished liver reserve. This study addresses this crucial gap by performing a single-center, retrospective analysis of 94 uHCC patients treated with ICIs plus AAs between 2020 and 2024. Among them, 63 had Child-Pugh A (CP A) cirrhosis, while 31 presented with CP B cirrhosis, allowing for a comparative evaluation of treatment outcomes and tolerability.

The study’s findings reveal an encouraging overall objective response rate (ORR) of 44.7% across the whole cohort, with a disease control rate (DCR) of 72.3%. These clinical endpoints offer a promising perspective on the tumor response to combination therapy in a population with traditionally poor prognoses. Median progression-free survival (mPFS) was reported at 6.3 months, and notably, the median overall survival (mOS) reached 28.3 months, underscoring sustained benefits in systemic therapy for uHCC patients.

When stratified by liver function status, patients with CP A cirrhosis exhibited higher ORR (50.8%) compared to those with CP B cirrhosis (32.3%), though this difference approached but did not reach statistical significance (P = 0.089). Similarly, DCR and mPFS were numerically superior in the CP A group but lacked statistical significance. Intriguingly, mOS demonstrated a marked and statistically significant disparity, favoring the CP A group (39.2 months) over CP B patients (15.9 months, P = 0.035). This dichotomy highlights the profound impact of hepatic functional reserve on long-term survival despite comparable response rates to therapy.

Several prognostic factors independent of cirrhosis status emerged from the analysis. Poor performance status, denoted by an Eastern Cooperative Oncology Group (ECOG) score of 2, prior treatments, and absence of concurrent locoregional therapies were associated with diminished objective responses. Additionally, CP B cirrhosis and advanced Barcelona Clinic Liver Cancer (BCLC) stages C or D independently predicted worse overall survival, underscoring the nuanced interactions between tumor burden, liver function, and systemic therapy efficacy.

The safety profile of ICIs combined with AAs was carefully assessed, revealing that an overwhelming majority (93.6%) of patients experienced at least one treatment-related adverse event (TRAE), with 27.7% encountering grade 3 or higher toxicities. Crucially, the incidence and severity of TRAEs did not differ significantly between CP A and CP B subgroups, suggesting that the addition of ICIs and AAs does not disproportionately increase treatment-related risks even in patients with moderately impaired liver function.

Remarkably, 32.3% of patients with CP B cirrhosis demonstrated improvement in their Child-Pugh score following systemic therapy, indicating a potential for therapeutic intervention to not only control tumor progression but also enhance hepatic functional reserve. This finding challenges conventional therapeutic nihilism associated with CP B patients and advocates for a more inclusive approach in clinical practice.

Understanding the mechanistic underpinnings of ICIs combined with AAs in uHCC is essential. Immune checkpoint inhibitors function by unleashing the immune system’s cytotoxic T cells against tumor cells, a mechanism often suppressed in the tumor microenvironment. Antiangiogenic agents complement this by inhibiting vascular endothelial growth factor (VEGF) pathways, effectively starving the tumor of its blood supply and promoting an immunologically active milieu. Their synergy is thought to enhance antitumor immunity and counteract resistance pathways frequently encountered in hepatocellular carcinoma.

The study’s retrospective design, although inherently limited by potential selection biases and confounding variables, offers valuable real-world insights. Incorporating patients with CP B cirrhosis, typically excluded from randomized trials, enhances the generalizability of findings and contributes toward personalized treatment paradigms. However, larger, prospective studies are essential to validate these observations and elucidate optimal treatment sequencing and combination strategies.

Previous research on systemic therapies in uHCC mainly focused on patients with preserved liver function, limiting evidence for CP B populations. This study significantly advances the field by demonstrating that systemic immunotherapy combined with antiangiogenic treatment can be both efficacious and tolerable in these patients, opening new therapeutic avenues. The observed survival benefit and Child-Pugh score improvements further emphasize the need to reconsider exclusion criteria in future clinical trials.

Translating these findings into clinical practice necessitates careful patient selection and monitoring. While ICIs plus AAs show robust efficacy, attention to adverse events remains paramount, particularly in patients with compromised liver function. The comparable safety profiles between Child-Pugh groups provide reassurance but warrant vigilant management to optimize outcomes.

The integration of locoregional therapies alongside systemic treatments appeared to improve objective response rates, underscoring the potential benefit of multimodal approaches in managing uHCC. Combining transarterial chemoembolization, radiofrequency ablation, or other localized interventions with ICIs and AAs may potentiate antitumor effects and prolong survival, as suggested by the independent predictive value of simultaneous locoregional therapy.

Moreover, patient performance status remained a critical determinant of treatment success, emphasizing the importance of pre-treatment evaluation and supportive care to maintain functional capacity. Incorporating comprehensive assessments and potential interventions to improve performance status might broaden eligibility and enhance clinical benefit.

This study’s implications extend beyond clinical outcomes, prompting a paradigm shift in conceptualizing systemic therapy candidacy for uHCC patients with advanced liver disease. By demonstrating safety and efficacy in CP B patients, it challenges existing treatment algorithms and supports a more nuanced, inclusive therapeutic approach balancing risk and benefit.

In conclusion, the retrospective analysis conducted at Beijing You’an Hospital highlights the promise of combining immune checkpoint inhibitors with antiangiogenic agents in the management of unresectable hepatocellular carcinoma among patients with varied liver function statuses. While significant survival differences remain linked to hepatic reserve, the overall favorable safety profile and some improvements in liver function underscore the potential to expand treatment access and improve outcomes for historically underserved patient groups in oncology.

Further well-structured prospective trials with larger cohorts and longer follow-up are imperative to refine patient stratification, optimize dosing regimens, and elucidate combinatory strategies involving ICIs, AAs, and locoregional therapies. Such investigations will be foundational to establishing new standards of care in hepatocellular carcinoma treatment, ultimately aiming to enhance survival and quality of life for patients within this challenging clinical context.

Subject of Research: Evaluation of the efficacy and safety of immune checkpoint inhibitors combined with antiangiogenic agents in unresectable hepatocellular carcinoma patients with Child-Pugh A versus B cirrhosis.

Article Title: Comparative efficacy and safety of immune checkpoint inhibitors combined with antiangiogenic agents for unresectable hepatocellular carcinoma in patients with Child-Pugh A versus B cirrhosis: a single-center, retrospective study.

Article References:
Liu, D., Yang, Z., Wang, L. et al. Comparative efficacy and safety of immune checkpoint inhibitors combined with antiangiogenic agents for unresectable hepatocellular carcinoma in patients with Child-Pugh A versus B cirrhosis: a single-center, retrospective study. BMC Cancer 25, 1651 (2025). https://doi.org/10.1186/s12885-025-15126-4

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-15126-4